STOCK TITAN
  1. Home
  2. News
  3. NTLA

Intellia Therape - NTLA STOCK NEWS

Welcome to our dedicated page for Intellia Therape news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therape stock.

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology leader pioneering CRISPR/Cas9 gene editing therapies. This page serves as the definitive source for official company announcements, including clinical trial updates, regulatory milestones, and strategic partnerships.

Investors and researchers will find curated press releases detailing NTLA's progress in treating genetic disorders like hereditary angioedema and ATTR amyloidosis. Content spans therapeutic pipeline developments, intellectual property advancements, and collaborative research initiatives with industry partners.

All materials are organized to facilitate quick scanning of critical updates while maintaining technical accuracy. Regular updates ensure stakeholders stay informed about NTLA's work in precision gene editing without promotional bias.

Bookmark this page for direct access to Intellia's latest financial reports, scientific publications, and conference participation details. Check back frequently for real-time updates on CRISPR-based therapeutic innovations.

News

Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones

Rhea-AI Summary
Intellia Therapeutics, a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, announced its strategic priorities through 2026 and key anticipated 2024 milestones. The company ended 2023 in a strong financial position with approximately $1.0 billion in cash and is on track to dose the first patient in the pivotal Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy in Q1 2024. Intellia aims to transform the lives of patients and bring forth a new era in medicine by advancing its pipeline and platform innovations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
none
-
News

Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

Rhea-AI Summary
Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced that the European Commission has granted orphan drug designation to NTLA-2002, an in vivo CRISPR-based investigational therapy for the treatment of hereditary angioedema (HAE). The orphan drug designation provides regulatory, financial, and commercial incentives to develop therapies for rare diseases. Intellia has received five special regulatory designations for NTLA-2002, indicating significant progress in the development of potential one-time treatment for people with HAE.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.09%
Tags
clinical trial
-
News

Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Rhea-AI Summary
Intellia Therapeutics, Inc. (NASDAQ:NTLA) has received FDA clearance for NTLA-2001, the first in vivo CRISPR candidate to enter late-stage clinical development. The company plans to initiate the MAGNITUDE pivotal Phase 3 trial for patients with ATTR amyloidosis with cardiomyopathy by year-end. Clinical data showed consistent, deep, and durable serum TTR reduction after a single dose of NTLA-2001, with over 90% median serum TTR reduction. The company also reported a strong financial position with $992.5 million in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.27%
Tags
earnings
News

Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting

Rhea-AI Summary
Intellia Therapeutics presents positive interim results from its Phase 1 study of NTLA-2001, an investigational CRISPR-based therapy for ATTR amyloidosis. The study shows consistent and deep reductions in serum TTR levels with a single dose of NTLA-2001. The 55 mg dose has been selected for further evaluation in a Phase 3 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.84%
Tags
clinical trial
-
News

Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November

Rhea-AI Summary
Intellia Therapeutics announces upcoming events in November: presentation of NTLA-2001 clinical data at the 4th International ATTR Amyloidosis Meeting and Q3 earnings webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
conferences earnings clinical trial
-
News

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Rhea-AI Summary
Intellia Therapeutics receives FDA clearance for NTLA-2001 gene editing therapy for ATTR amyloidosis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
clinical trial
News

Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

Rhea-AI Summary
Intellia Therapeutics Receives PRIME Designation for NTLA-2002 in the Treatment of Hereditary Angioedema
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
none
-
News

Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

Rhea-AI Summary
Regeneron and Intellia expand collaboration to develop CRISPR-based gene editing therapies for neurological and muscular diseases. Collaboration combines Intellia's genome editing platform with Regeneron's viral vector delivery technologies. Companies will initially research two non-liver targets. Each company has the opportunity to lead development and commercialization for one target.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
none
-
News

Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Rhea-AI Summary
Intellia Therapeutics reports operational highlights and financial results for Q2 2023. They have completed patient identification for Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) and plan to initiate Phase 3 study in Q3 2024. They also plan to submit IND application for NTLA-2001 for ATTR amyloidosis and present additional clinical data in 2023. They expect to submit CTA for NTLA-3001 for alpha-1 antitrypsin deficiency (AATD)-associated lung disease. They ended Q2 2023 with $1.1 billion in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
earnings
News

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates

Rhea-AI Summary
Intellia Therapeutics, Inc. (NASDAQ:NTLA) to present Q2 2023 financial results and operational highlights on August 3, 2023. Join the conference call for insights into the company's progress and future prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
earnings
Stock NTLA logo
Intellia Therape

Nasdaq:NTLA

NTLA Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

NTLA Stock Data

748.43M
97.95M
5.05%
91.72%
25.15%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States
CAMBRIDGE